<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Locoregional mucosal melanoma: Epidemiology, clinical diagnosis, and treatment
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Locoregional mucosal melanoma: Epidemiology, clinical diagnosis, and treatment
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Locoregional mucosal melanoma: Epidemiology, clinical diagnosis, and treatment
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard D Carvajal, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Omid Hamid, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Charlotte Ariyan, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael B Atkins, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Russell S Berman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Melinda Yushak, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 18, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2013333759">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mucosal melanomas generally arise from the mucosal epithelium lining the respiratory, alimentary, and genitourinary tracts, all of which contain melanocytes. Melanoma can also arise from melanocytes within the skin, which is classified as cutaneous melanoma.
        </p>
        <p>
         Mucosal melanomas generally carry a worse prognosis than those arising from cutaneous sites. Our understanding of the optimal management for mucosal melanoma is limited because of the rarity of this disease, its unique biology, and clinical challenges of mucosal melanoma arising from each anatomic location.
        </p>
        <p>
         The epidemiology, clinical presentation, and management of patients with locoregional mucosal melanoma arising in the head and neck, vulvovaginal, and anorectal regions are discussed here. The management of patients with metastatic mucosal melanoma, cutaneous melanoma, and uveal and conjunctival melanoma is discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/138441.html" rel="external">
          "Treatment of metastatic mucosal melanoma"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/85841.html" rel="external">
          "Overview of the management of advanced cutaneous melanoma"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7615.html" rel="external">
          "Adjuvant and neoadjuvant therapy for cutaneous melanoma"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15863.html" rel="external">
          "Systemic treatment of metastatic melanoma lacking a BRAF mutation"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15408.html" rel="external">
          "Systemic treatment of metastatic melanoma with BRAF and other molecular alterations"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7617.html" rel="external">
          "Initial management of uveal and conjunctival melanomas"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H32370021">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mucosal melanoma has distinct epidemiologic and clinical features that differentiate it from cutaneous melanoma and have important implications for patient management.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Incidence
         </strong>
         – Mucosal melanoma represents approximately 1.3 percent of the melanomas in the United States and accounts for an estimated incidence of 1400 patients [
         <a href="#rid1">
          1,2
         </a>
         ]. Although the incidence of cutaneous melanoma has been increasing rapidly in the United States, the incidence of mucosal melanoma has generally remained stable over time [
         <a href="#rid3">
          3,4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anatomic sites
         </strong>
         – Mucosal melanomas arise primarily in the head and neck, anorectal, and vulvovaginal regions (55, 24, and 18 percent of cases, respectively). Rarer sites of origin include the urinary tract, gallbladder, and small intestine.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Age and sex
         </strong>
         – In general, patients diagnosed with mucosal melanomas are older, with a median age of 70 years. However, mucosal melanoma of the oral cavity presents in younger patients (mean age of 55 years) [
         <a href="#rid5">
          5-8
         </a>
         ]. Mucosal melanoma is more common in females than males, primarily due to the development of disease in the genital tract [
         <a href="#rid1">
          1,9,10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
         – Cutaneous melanoma is associated with exposure to ultraviolet light, but the anatomic location of mucosal melanoma precludes ultraviolet exposure as a risk factor, with the exception of conjunctival melanoma [
         <a href="#rid11">
          11
         </a>
         ]. No clear environmental or other predisposing risk factors have been identified in this disease. (See
         <a class="medical medical_review" href="/z/d/html/4844.html" rel="external">
          "Melanoma: Epidemiology and risk factors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Multifocal, amelanotic tumors
         </strong>
         – An estimated 20 percent of mucosal melanomas are multifocal [
         <a href="#rid12">
          12
         </a>
         ], compared with less than 5 percent of those arising in the skin [
         <a href="#rid13">
          13
         </a>
         ]. Approximately 40 percent of mucosal melanomas are amelanotic, compared with less than 10 percent of cutaneous melanomas [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Metastatic disease
         </strong>
         – Mucosal melanoma patients are more likely to present with metastatic disease at the time of diagnosis compared with cutaneous melanoma (23 versus 5 percent) [
         <a href="#rid1">
          1,14
         </a>
         ]. This is primarily due to lack of visibility of the primary site and absence of clinical symptoms, which frequently leads to a delay in diagnosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Mucosal melanoma has a more aggressive underlying biology compared with other melanoma subtypes, which may also influence disease stage at presentation. Patients with mucosal melanoma have a five-year overall survival (OS) rate of only 25 percent [
         <a href="#rid1">
          1
         </a>
         ], and they also have inferior stage-matched survival compared with other melanoma subtypes, both at the time of diagnosis and at the development of metastatic disease [
         <a href="#rid15">
          15,16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ethnicity
         </strong>
         – Mucosal melanomas make up a greater proportion of all melanomas diagnosed in Black, Asian, and Hispanic individuals when compared with melanomas occurring in White individuals, reflecting the much lower incidence of cutaneous melanoma in these populations [
         <a href="#rid17">
          17
         </a>
         ]. Melanomas of mucosal origin comprise up to 25 percent of all melanomas diagnosed in Chinese patients (most prospective trials are derived from this population), 9 percent of all melanomas diagnosed in Black or Hispanic patients, and less than 2 percent of all melanomas diagnosed in non-Hispanic White patients [
         <a href="#rid1">
          1,18
         </a>
         ]. Despite a greater proportion of mucosal melanomas in Black, Asian, and Hispanic populations, the absolute incidence of mucosal melanoma remains greater in White populations.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1799107090">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The definitive diagnosis of mucosal melanoma of any primary site is made using biopsy and histopathology, which is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15806.html" rel="external">
          "Melanoma: Clinical features and diagnosis", section on 'Diagnosis confirmation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3258771452">
         <span class="h1">
          MANAGEMENT CONSIDERATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H32370271">
         <span class="h2">
          Surgical considerations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regardless of the primary site, initial management for locoregionally confined mucosal melanoma is complete wide local surgical resection. Complete surgical resection, if feasible, offers the best chance for prolonged disease-free survival. However, complete resection with optimal margins is frequently difficult because of the lentiginous growth pattern frequently associated with mucosal melanoma, disease multifocality, and anatomic constraints. Patient preferences and quality of life considerations are critical in determining the extent of surgery.
        </p>
        <p>
         The morbidity of an aggressive resection must also be balanced against the risk of metastatic disease. Most patients will ultimately develop distant metastases despite adequate local disease control of the primary disease with surgery. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1498304790">
         <span class="h2">
          Is there a role for neoadjuvant therapy?
         </span>
         <span class="headingEndMark">
          —
         </span>
         The role of neoadjuvant therapy in patients with mucosal melanoma is evolving. Further studies in this area may demonstrate the benefits of initial immunotherapy and lead to the development of predictive and prognostic biomarkers. Patients who are interested in this approach should be offered enrollment in clinical trials, where available. Further details on the role of neoadjuvant immunotherapy in advanced cutaneous melanoma are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7615.html" rel="external">
          "Adjuvant and neoadjuvant therapy for cutaneous melanoma"
         </a>
         .)
        </p>
        <p>
         In preliminary results from a phase II trial of 21 patients with resectable mucosal melanoma, at median follow-up of 59 weeks, neoadjuvant
         <a class="drug drug_general" data-topicid="143227" href="/z/d/drug information/143227.html" rel="external">
          toripalimab
         </a>
         and
         <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">
          axitinib
         </a>
         demonstrated a complete pathologic response rate of 29 percent [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3306310">
         <span class="h1">
          MUCOSAL MELANOMA OF THE HEAD AND NECK
         </span>
        </p>
        <p class="headingAnchor" id="H32357298">
         <span class="h2">
          Clinical presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mucosal melanomas account for less than 10 percent of all melanomas arising in the head and neck region. Mucosal melanomas of the head and neck commonly occur in the following locations [
         <a href="#rid20">
          20-25
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nasal cavity (most commonly involving the turbinates and nasal wall) – 55 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Paranasal sinuses (most commonly involving the maxillary and ethmoid sinuses) – 15 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oral cavity (most commonly involving the hard palate and upper alveolus) – 25 percent
        </p>
        <p>
        </p>
        <p>
         Much less commonly, mucosal melanomas arise in the pharynx [
         <a href="#rid26">
          26
         </a>
         ], larynx [
         <a href="#rid27">
          27
         </a>
         ], or esophagus [
         <a href="#rid28">
          28,29
         </a>
         ].
        </p>
        <p>
         Patients with sinonasal mucosal melanomas frequently present with nasal obstruction, epistaxis, or loss of smell [
         <a href="#rid30">
          30-32
         </a>
         ]. Mucosal melanoma of the oral cavity typically presents as a painless bleeding mass, as an area of ulceration, as a region of mucosal discoloration, or with ill-fitting dentures [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         Approximately 60 percent of mucosal melanomas arising from the oral cavity are identified incidentally during routine dental examination. Irregular isolated areas of pigmentation within the oral mucosa must be differentiated from melanosis, a benign condition which is common in Black patients and generally is symmetrical. Such lesions should be biopsied.
        </p>
        <p class="headingAnchor" id="H3306317">
         <span class="h2">
          Staging evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Upon diagnostic confirmation, the initial staging evaluation for patients with mucosal melanoma arising from the head and neck should include clinical examination with endoscopic inspection for paranasal disease, computed tomography (CT) and/or magnetic resonance imaging (MRI) of the primary site of disease, and CT of the neck, chest, abdomen, and pelvis and/or positron emission tomography (PET)-CT imaging to assess for lymph node involvement or distant metastases [
         <a href="#rid33">
          33
         </a>
         ]. Regional lymph node involvement at presentation has been estimated in approximately 25 percent of those with oral cavity lesions and 6 percent of those with sinonasal mucosal melanoma [
         <a href="#rid1">
          1
         </a>
         ]. Central nervous system (CNS) imaging is also obtained at diagnosis, as the brain can be observed as an initial site of metastasis in 7 percent of cases of mucosal melanoma [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1491442289">
         <span class="h2">
          Staging system
         </span>
         <span class="headingEndMark">
          —
         </span>
         The American Joint Committee on Cancer (AJCC) staging system for mucosal melanoma arising from the head and neck is generally used for this subset of disease and reflects the overwhelmingly poor prognosis of this disease  (
         <a class="graphic graphic_table graphicRef110810" href="/z/d/graphic/110810.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         The AJCC head and neck stage system differs from that for cutaneous melanoma, in which prognosis depends upon the local, regional, and distant burden of disease. Staging begins at stage III as the most limited form of disease, to reflect the poor prognosis in these patients, and includes three subcategories of stage IV disease (IVA, IVB, and IVC), depending upon the local extent and presence of regional and distant disease [
         <a href="#rid36">
          36-38
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H32356226">
         <span class="h2">
          Management of locoregional disease
         </span>
        </p>
        <p class="headingAnchor" id="H32364903">
         <span class="h3">
          Surgical candidates
         </span>
         <span class="headingEndMark">
          —
         </span>
         Complete surgical excision is the primary treatment for AJCC stage III and IVA mucosal melanomas of the head and neck if the lesion can be resected with negative margins. Surgery is not typically used as primary therapy for patients with lymph node involvement (IVB) or distant metastases (IVC), unless there is a need for local control of disease. Patients with complete resection may be evaluated for adjuvant radiation therapy (RT), although treatment is individualized. (See
         <a class="local">
          'Adjuvant radiation'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1074554139">
         <span class="h4">
          Management of the primary site
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mucosal melanomas of the oral cavity are approached surgically in the same manner as squamous cell carcinomas at the same site. Local resection should be accompanied by appropriate reconstruction using free flaps for mandibular, soft tissue, or structural defects. Similarly, mucosal melanoma of the larynx and pharynx should be managed by the appropriate surgical approach to achieve local control.
        </p>
        <p>
         Craniofacial resection has been used when tumor invades the skull base, either as part of the initial presentation or as an isolated local recurrence [
         <a href="#rid39">
          39,40
         </a>
         ]. Endoscopic resections are being performed more commonly and may be accomplished with less morbidity and equivalent local control [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         Despite aggressive surgical management, local recurrence is common [
         <a href="#rid5">
          5,22,25,31
         </a>
         ]. Factors associated with local recurrence include tumor size, incomplete resection, and vascular invasion [
         <a href="#rid22">
          22,42
         </a>
         ]. The median time to first recurrence in the head and neck is 6 to 12 months [
         <a href="#rid20">
          20,31
         </a>
         ]. (See
         <a class="local">
          'Prognosis'
         </a>
         below.)
        </p>
        <p>
         Although the initial site of relapse is frequently local or regional, such recurrence usually is a harbinger of disseminated disease, with most patients dying of distant rather than uncontrolled local disease [
         <a href="#rid5">
          5,20,30,43,44
         </a>
         ]. Additional surgery can be considered for locally recurrent disease; however, the decision to proceed with re-resection for local or regional recurrence should be evaluated on a case-by-case basis.
        </p>
        <p class="headingAnchor" id="H649250434">
         <span class="h4">
          Management of the neck
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surgical management of the neck depends upon the presence or absence of clinical nodal disease and disease location (sinonasal versus oral cavity). General principles are as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinically negative nodes
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with sinonasal mucosal melanoma and clinically negative neck nodes, we suggest surveillance alone rather than elective lymph node dissection. In this population, the incidence of nodal disease is relatively low (between 10 and 17 percent) [
         <a href="#rid22">
          22,45
         </a>
         ]. (See
         <a class="local">
          'Surveillance'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with mucosal melanoma arising from the oral cavity and clinically negative neck nodes, we suggest elective lymph node dissection rather than observation for control of nodal disease [
         <a href="#rid46">
          46
         </a>
         ]. In this population, the incidence of nodal disease is estimated at up to 25 percent [
         <a href="#rid22">
          22,25
         </a>
         ]. As in squamous cell carcinoma of the head and neck, the regional lymph nodes can be addressed at the same time as the primary resection, clearing the first and second echelons of nodes. Furthermore, when reconstruction using free flaps is required after primary resection, the neck must be entered and the nodal basin exposed, which allows for evaluation and clearance of nodal disease at that time.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Sentinel lymph node biopsy does not have an established role in patients with mucosal melanoma of the head and neck, although successful identification of sentinel lymph nodes in patients with mucosal melanoma is feasible [
         <a href="#rid47">
          47,48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinically evident nodal disease
         </strong>
         – For patients with clinically evident nodal disease, therapeutic neck dissection can be offered based on the need for local control and symptoms [
         <a href="#rid45">
          45
         </a>
         ]. Therapeutic neck dissection can be accomplished with limited morbidity and may be performed for optimal regional control. However, no significant difference in five-year overall survival (OS) has been observed in patients with and without lymph node recurrence [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H32364415">
         <span class="h4">
          Adjuvant radiation
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with high-risk disease (palpable lymph nodes or extracapsular extension), we suggest adjuvant RT. Adjuvant RT may reduce local recurrences following wide local excision and neck dissection in patients with high-risk features such as palpable lymph nodes or extracapsular extension [
         <a href="#rid38">
          38
         </a>
         ], although no OS benefit has been demonstrated. Treatment decisions should be individualized, as there are limited prospective clinical trials and optimal dosing and fractionation schedules have not been established. (See
         <a class="medical medical_review" href="/z/d/html/3374.html" rel="external">
          "Adjuvant radiation therapy or chemoradiation in the management of head and neck cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7614.html" rel="external">
          "Radiation therapy in the management of melanoma"
         </a>
         .)
        </p>
        <p>
         Local recurrence occurs in 29 to 79 percent of cases despite aggressive surgery and can be clinically devastating [
         <a href="#rid5">
          5,25,43,49-51
         </a>
         ]. Observational data and one meta-analysis evaluating adjuvant RT have reported an improvement in locoregional control but no impact on survival [
         <a href="#rid32">
          32,43,51-55
         </a>
         ]. Such benefit, however, has not been observed in all series [
         <a href="#rid22">
          22,56
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H714395346">
         <span class="h3">
          Nonsurgical candidates
         </span>
         <span class="headingEndMark">
          —
         </span>
         Definitive, or primary, RT may be an alternative option for patients who are not surgical candidates or in whom a complete resection is not feasible (eg, inability to obtain adequate resection margins or anatomic constraints) [
         <a href="#rid43">
          43
         </a>
         ]. However, such treatment decisions are individualized, as there are limited prospective clinical trials and optimal dosing and fractionation schedules have not been established. (See
         <a class="medical medical_review" href="/z/d/html/7614.html" rel="external">
          "Radiation therapy in the management of melanoma"
         </a>
         .)
        </p>
        <p>
         Tumor control rates ranging from 61 to 85 percent have been reported with definitive RT in patients with mucosal melanomas arising from the head and neck [
         <a href="#rid57">
          57,58
         </a>
         ]. Analysis of these series is complicated by the selection bias toward the use of RT in patients with more extensive tumors and narrow or involved surgical margins.
        </p>
        <p class="headingAnchor" id="H32367986">
         <span class="h2">
          Prognosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prognosis in patients with mucosal melanoma arising in the head and neck is generally poor. The five-year survival rates range between 12 to 30 percent for primary lesions of the nasal cavity, oral cavity, and paranasal sinuses. Better outcomes are observed for mucosal melanoma arising from the nasal cavity and inferior outcomes for those with disease arising from the paranasal sinuses [
         <a href="#rid22">
          22,38,59-61
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3306331">
         <span class="h1">
          VULVOVAGINAL MELANOMA
         </span>
        </p>
        <p class="headingAnchor" id="H905034685">
         <span class="h2">
          Clinical presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Melanomas arising from the female urogenital tract occur primarily in the vulva and vagina (95 and 3 percent, respectively) [
         <a href="#rid1">
          1
         </a>
         ]. Vulvar melanomas represent 10 percent of all malignant tumors involving the vulva, but less than 1 percent of all melanomas [
         <a href="#rid62">
          62,63
         </a>
         ]. Melanomas arising elsewhere in the urogenital tract (ie, urinary bladder, urethra, or cervix) are rarer [
         <a href="#rid64">
          64-68
         </a>
         ]. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
         Patients with vulvovaginal melanoma commonly present with pruritus, vaginal bleeding, a vaginal discharge, dyspareunia, or a mass [
         <a href="#rid69">
          69-74
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3819982176">
         <span class="h2">
          Risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         A subset of vulvar melanomas may share common risk factors with cutaneous melanoma, particularly those arising from the outer, nonglabrous hair-bearing portion of the labia majora, Some vulvar melanomas may develop from contiguous nevi [
         <a href="#rid75">
          75
         </a>
         ]. Chronic inflammatory disease, viral infections, chemical irritants, and genetic factors have also been implicated as risk factors [
         <a href="#rid76">
          76
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3237.html" rel="external">
          "Vulvar cancer: Epidemiology, diagnosis, histopathology, and treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3306338">
         <span class="h2">
          Staging evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Upon diagnostic confirmation, the initial staging evaluation for patients with vulvovaginal melanoma should include clinical assessment with pelvic examination, CT and/or MRI of the primary site of disease, and CT of the chest, abdomen, and pelvis and/or positron emission tomography (PET)-CT imaging to assess for the presence of distant disease [
         <a href="#rid77">
          77
         </a>
         ]. Central nervous system (CNS) imaging with brain MRI is also obtained at diagnosis [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1161823">
         <span class="h2">
          Staging system
         </span>
        </p>
        <p class="headingAnchor" id="H3926042923">
         <span class="h3">
          Vulvar melanoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vulvar melanomas should be staged according to the tumor, node, metastasis (TNM) system for cutaneous melanoma [
         <a href="#rid77">
          77
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7618.html" rel="external">
          "Tumor, node, metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma", section on 'Eighth edition AJCC TNM staging'
         </a>
         .)
        </p>
        <p>
         Outcomes based on stage of disease at presentation are illustrated by the five-year relative survival rates in 223 women diagnosed between 1985 and 1989 in the United States based upon data in the National Cancer Database [
         <a href="#rid62">
          62
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stage 0
         </strong>
         – 77 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stage I
         </strong>
         – 70 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stage II
         </strong>
         – 50 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stage III
         </strong>
         – 48 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stage IV
         </strong>
         – 24 percent
        </p>
        <p>
        </p>
        <p>
         The Gynecologic Oncology Group performed a prospective clinical-pathologic study of primary vulvar melanomas evaluating the predictive value of the microscopic staging systems described by Clark [
         <a href="#rid78">
          78
         </a>
         ], Breslow [
         <a href="#rid79">
          79
         </a>
         ], and Chung [
         <a href="#rid80">
          80
         </a>
         ], as well as the International Federation of Gynecology and Obstetrics (FIGO) system and the 1992 American Joint Committee on Cancer (AJCC) melanoma staging system. In this study, the AJCC cutaneous melanoma staging system was found to be the most significant predictor of recurrence-free survival in females with this disease [
         <a href="#rid81">
          81
         </a>
         ]. Subsequent studies have provided additional evidence that using the modified AJCC staging system for cutaneous melanoma has prognostic utility for vulvar melanoma [
         <a href="#rid82">
          82,83
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1626039006">
         <span class="h3">
          Vaginal melanoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vaginal melanoma are classified using a simplified three-stage clinical system [
         <a href="#rid18">
          18,84
         </a>
         ]. In this system, stages I, II, and III correspond to clinically localized disease, regional lymph node involvement, and distant metastases, respectively.
        </p>
        <p>
         No particular staging system is a useful predictor of prognosis for vaginal melanoma, although tumor size (&lt;3 cm versus ≥3 cm), has been shown to predict survival in some series [
         <a href="#rid85">
          85,86
         </a>
         ]. This three-stage system, which was initially developed for mucosal melanomas of the head and neck, has limited prognostic utility for vaginal mucosal melanoma because a majority of patients present with localized (stage I) disease. However since it is easy to use and broadly applicable, it remains a reasonable staging system for vaginal melanoma, in the absence of a predictive alternative.
        </p>
        <p class="headingAnchor" id="H32356678">
         <span class="h2">
          Management of locoregional disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with vulvovaginal melanoma, we suggest wide local excision of the primary tumor rather than more radical surgical approaches, as data have not demonstrated an overall survival (OS) benefit with more morbid surgery. Additionally, most patients ultimately develop distant metastatic disease regardless of the primary surgical procedure [
         <a href="#rid87">
          87
         </a>
         ]. Therefore, patient preference and quality-of-life considerations are critical factors in determining the extent of surgery for the initial management.
        </p>
        <p class="headingAnchor" id="H1161488">
         <span class="h3">
          Vulvar melanoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Wide local excision has generally replaced pelvic exenteration for vulvovaginal melanoma for patients without evidence of distant metastases. Surgical management of vulvar melanomas should include resection of the primary tumor by wide local excision. Radical vulvectomy is reserved for large tumors primarily to obtain local disease control. Melanomas &lt;1 mm thick should be treated with 1 cm skin margins; if anatomically feasible, margins can be extended to 2 cm for thicker melanomas [
         <a href="#rid88">
          88,89
         </a>
         ]. The excision contains all layers of skin and subcutaneous tissues, extending to the muscular fascia below.
        </p>
        <p>
         More radical procedures are associated with significant morbidity. Although some series suggested improved local control with more aggressive surgical procedures, the impact of improved local control upon survival is limited by the concomitant development of distant metastases in the majority of cases. Retrospective data also suggest no difference in OS with more conservative wide local excision [
         <a href="#rid82">
          82,85,90-96
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1161692">
         <span class="h3">
          Vaginal melanoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Standard management of patients with vaginal melanoma involves wide local excision if possible. Achieving negative margins in these cases can be difficult without pelvic exenteration given the high frequency of multifocality and anatomic constraints. However, the impact of such radical surgery upon survival when compared with more conservative procedures (with or without radiation therapy [RT]) is unclear. Thus, surgery may be combined with RT in select cases. (See
         <a class="local">
          'Adjuvant radiation'
         </a>
         above.) [
         <a href="#rid97">
          97
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1161713">
         <span class="h3">
          Regional lymph nodes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evaluation of sentinel nodes is feasible in patients with vulvovaginal melanoma, but the role of this approach is uncertain [
         <a href="#rid76">
          76,98,99
         </a>
         ]. A positive sentinel lymph node biopsy can identify patients with locoregionally advanced nodal disease who may qualify for additional adjuvant systemic therapy. However, elective regional lymphadenectomy does not provide a survival benefit. (See
         <a class="local">
          'Resected locoregional lymph nodes (adjuvant therapy)'
         </a>
         below.)
        </p>
        <p>
         While small series suggest a survival benefit for elective regional lymphadenectomy in patients with vulvar melanoma, a more contemporary study performed by the Gynecologic Oncology Group identified positive nodes as merely a prognostic factor along with tumor thickness. In this series, only 7 out of 56 patients undergoing a lymphadenectomy had positive nodes [
         <a href="#rid81">
          81
         </a>
         ]. In addition, several studies have demonstrated that radical vulvectomy with bilateral inguinofemoral lymphadenectomy does not confer a survival benefit when compared with wide local excision alone for vulvar melanoma [
         <a href="#rid95">
          95,100
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H32369212">
         <span class="h2">
          Prognosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite aggressive therapy, the prognosis remains poor for most patients with mucosal melanoma arising in the vulva or vagina. While patients with vulvar melanoma have five-year survival rates of 24 to 77 percent, those with vaginal melanoma have five-year survival rates of 5 to 25 percent [
         <a href="#rid71">
          71,88,101-105
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3306352">
         <span class="h1">
          ANORECTAL MELANOMA
         </span>
        </p>
        <p class="headingAnchor" id="H32357337">
         <span class="h2">
          Clinical presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anorectal mucosal melanoma accounts for approximately 0.05 percent of all colorectal malignancies and 1 percent of all anal canal cancers [
         <a href="#rid106">
          106
         </a>
         ]. The site of origin is the rectum or anal canal in 42 and 33 percent of cases, respectively, while the primary site cannot be determined in the remainder. Although the risk factors for anorectal mucosal melanoma are not known, epidemiologic data suggest that there is an increased risk associated with human immunodeficiency virus infection [
         <a href="#rid106">
          106-108
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8036.html" rel="external">
          "HIV infection and malignancy: Management considerations", section on 'Melanoma'
         </a>
         .)
        </p>
        <p>
         The majority of cases arise from the mucocutaneous junction; however, they can also arise from the skin of the anal verge, the transitional epithelium of the anal canal, or the rectal mucosa  (
         <a class="graphic graphic_figure graphicRef62539" href="/z/d/graphic/62539.html" rel="external">
          figure 1
         </a>
         ). While primary site of disease in vulvovaginal melanoma has prognostic relevance, this is not the case for anorectal melanoma [
         <a href="#rid109">
          109
         </a>
         ].
        </p>
        <p>
         Patients typically present with bleeding, a mass, anorectal pain, or a change in bowel habits. Occasionally, melanoma is an incidental finding on pathologic evaluation of a hemorrhoidectomy or anal polyp specimen. Anorectal melanoma is pigmented in only one-third of cases. Most patients present with lesions that are &gt;2 mm thick. Regional lymph node involvement is found in approximately 60 percent of patients at presentation [
         <a href="#rid1">
          1
         </a>
         ], and distant metastases are present at diagnosis in approximately 30 percent of cases [
         <a href="#rid110">
          110-115
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3306359">
         <span class="h2">
          Staging evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Upon diagnostic confirmation, the initial staging evaluation of patients with anorectal melanoma should include a rectal examination, possible rectal ultrasound, and CT of the chest, abdomen, and pelvis and/or positron emission tomography (PET)-CT imaging to assess for distant metastases. Central nervous system (CNS) imaging with brain MRI is also obtained at the time of diagnosis [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2402097370">
         <span class="h2">
          Staging system
         </span>
         <span class="headingEndMark">
          —
         </span>
         Retrospective series have used a simple system in which localized disease only, regional lymph node involvement, and distant metastases are classified as stages I, II, and III, respectively [
         <a href="#rid116">
          116
         </a>
         ].
        </p>
        <p>
         Factors that may adversely affect prognosis in patients with localized disease include the presence of perineural invasion, tumor size and thickness, and the presence of amelanotic melanoma [
         <a href="#rid111">
          111,112,117-119
         </a>
         ].
        </p>
        <p>
         Patients with lymph node metastases or distant metastases at presentation have an especially poor prognosis. A review of 183 patients with anorectal mucosal melanoma identified in the Surveillance, Epidemiology, and End Results (SEER) database found the following [
         <a href="#rid110">
          110
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stage I
         </strong>
         – median survival, 24 months; five-year survival, 26.7 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stage II
         </strong>
         – median survival, 17 months; five-year survival, 9.8 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stage III
         </strong>
         – median survival, 8 months; five-year survival, 0 percent
        </p>
        <p>
        </p>
        <p>
         Although anorectal melanoma is excluded from the American Joint Committee on Cancer (AJCC) staging system for anal cancers, a modification of the AJCC eighth edition staging system for cutaneous melanoma where T stage is classified into three groups: thin (T1), intermediate (T2 to T3), and thick (T4), can be used to stratify patients for survival [
         <a href="#rid120">
          120
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3306422">
         <span class="h2">
          Management of locoregional disease
         </span>
        </p>
        <p class="headingAnchor" id="H32364273">
         <span class="h3">
          Surgery (primary tumor)
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients, we suggest wide local, sphincter-sparing excision rather than abdominoperineal resection, as morbidity is higher with abdominoperineal resection and the benefit of local control with more aggressive surgery is limited by the risk of distant metastases regardless of the primary surgical procedure.
        </p>
        <p>
         The primary goal of surgery is to perform a negative margin, sphincter-sparing excision. Abdominoperineal resection is reserved for patients with bulky local disease and for carefully selected patients with local recurrence [
         <a href="#rid121">
          121
         </a>
         ].
        </p>
        <p>
         Multiple observational studies have looked at the impact of the extent of surgery on long-term outcomes. Some series suggested improved local control with abdominoperineal resection, a procedure accompanied by a high morbidity rate and functional limitations [
         <a href="#rid115">
          115,117,122
         </a>
         ]; however, retrospective data suggest that there is no difference in overall survival (OS) with more conservative wide local excision [
         <a href="#rid110">
          110,111,118,123,124
         </a>
         ].
        </p>
        <p>
         The benefit of improved local control upon survival is limited. Most patients ultimately develop distant disease regardless of the primary surgical procedure; thus patient preference and quality-of-life considerations are critical in determining the extent of surgery.
        </p>
        <p>
         The most important factor in surgery appears to be the ability to achieve negative (R0) surgical resection margins [
         <a href="#rid118">
          118,123
         </a>
         ]. In a series of 251 cases from the Swedish National Cancer Registry, the five-year survival rates following surgical excision for those in whom an R0 resection was achieved was 19 percent, compared with 6 percent in those in whom a complete local excision was not possible [
         <a href="#rid123">
          123
         </a>
         ]. On multivariate analysis, resection status and tumor stage were significantly associated with prognosis, but the type of resection (abdominoperineal resection or local excision) was not significant.
        </p>
        <p class="headingAnchor" id="H4283271977">
         <span class="h3">
          Indications for inguinal lymphadenectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with clinically node-negative disease, we suggest against elective inguinal lymphadenectomy, given the morbidity of bilateral inguinal node dissection and lack of survival benefit from an elective dissection. Inguinal lymphadenectomy is reserved for patients with clinically apparent nodal disease.
        </p>
        <p>
         Mesorectal, pelvic sidewall, and inguinal lymph nodes are at risk for involvement in anorectal mucosal melanoma. However, available data suggest that lymph node metastasis does not predict outcome in patients undergoing radical resection, and sentinel lymph node biopsy does not have an established role in these patients [
         <a href="#rid118">
          118,125,126
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H32364266">
         <span class="h3">
          Adjuvant radiation therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adjuvant radiation therapy (RT) for anorectal melanoma may improve locoregional control despite a limited impact on OS [
         <a href="#rid127">
          127
         </a>
         ]. Patients who are being evaluated for adjuvant RT should be offered a balanced discussion about these clinical benefits versus the potential side effects of RT.
        </p>
        <p>
         Sphincter-sparing local excision followed by hypofractionated RT has been used as an alternative to abdominoperineal resection to prevent local recurrence. However, there are limited data on preserving quality of life with this approach in mucosal melanoma. In an observational series of 54 patients from MD Anderson Cancer Center treated over a 20-year period, this approach achieved local control in 82 percent of cases; however, the five-year OS rate was only 30 percent [
         <a href="#rid128">
          128
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H32369205">
         <span class="h2">
          Prognosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The reported five-year survival rates for patients with anorectal melanoma are approximately 20 percent [
         <a href="#rid117">
          117,118,123,129
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H32369551">
         <span class="h1">
          RESECTED LOCOREGIONAL LYMPH NODES (ADJUVANT THERAPY)
         </span>
        </p>
        <p class="headingAnchor" id="H1270663142">
         <span class="h2">
          Treatment approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with mucosal melanoma at high risk of recurrence, there are limited data for adjuvant systemic therapy, particularly in Western patient populations. Management decisions should be made on an individual basis. Patients should also be encouraged to enroll on clinical trials, where available. Our treatment approach is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           BRAF
          </em>
         </strong>
         <strong>
          wild-type tumors
         </strong>
         – For patients with tumors lacking a
         <em>
          BRAF
         </em>
         V600 mutation, options include adjuvant chemotherapy (
         <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">
          temozolomide
         </a>
         plus
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         ) or adjuvant immunotherapy; either treatment is reasonable in the absence of comparative data. Expectant observation may be offered to those who are ineligible for or decline adjuvant systemic therapy. (See
         <a class="local">
          'Surveillance'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           BRAF
          </em>
         </strong>
         <strong>
          mutant tumors
         </strong>
         – For the uncommon patient with a
         <em>
          BRAF
         </em>
         V600 mutation-positive tumor (less than ten percent of all mucosal melanomas [
         <a href="#rid130">
          130
         </a>
         ]), targeted therapy with
         <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">
          dabrafenib
         </a>
         plus
         <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">
          trametinib
         </a>
         is also an option, in addition to adjuvant approaches available for
         <em>
          BRAF
         </em>
         wild-type mucosal melanoma. Management of these patients is extrapolated from those with
         <em>
          BRAF
         </em>
         mutant cutaneous melanoma who receive adjuvant systemic therapy, and is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7615.html" rel="external">
          "Adjuvant and neoadjuvant therapy for cutaneous melanoma", section on 'BRAF-mutated tumors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H851532267">
         <span class="h2">
          Adjuvant chemotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adjuvant chemotherapy (
         <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">
          temozolomide
         </a>
         plus
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         ) improved relapse-free survival benefit in randomized trials of patients with mucosal melanoma and resected regional lymph nodes [
         <a href="#rid131">
          131,132
         </a>
         ]. However, most studies were conducted in Asian populations and require further study in a broader patient population before adjuvant chemotherapy can be offered as a standard of care for Western patients with mucosal melanoma. This approach might be an option in carefully selected patients who are not candidates for clinical trials, have undergone a potentially curative resection, have no serious coexisting illness, and have the potential for long-term survival excluding their risk of melanoma related mortality.
        </p>
        <p>
         Based on initial data from a phase II randomized trial [
         <a href="#rid131">
          131
         </a>
         ], a subsequent phase III trial was conducted in 204 with completely resected Stage I to III mucosal melanoma [
         <a href="#rid132">
          132
         </a>
         ]. Patients were randomly assigned to either adjuvant chemotherapy (
         <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">
          temozolomide
         </a>
         200 mg/m
         <sup>
          2
         </sup>
         days 1 to 5 plus
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         25 mg/m2 days 1 to 3, every three weeks for six cycles) or one year of adjuvant interferon-alfa-2b. In preliminary results, at median follow-up of 24 months, compared to interferon-alfa-2b, chemotherapy improved relapse-free survival (median 15.5 versus 9.5 months; hazard ratio [HR] 0.56; 95% CI 0.4-0.77) and distant metastasis-free survival (median 16.8 months versus 9.6 months, HR 0.53; 95% CI 0.38-0.74) [
         <a href="#rid132">
          132
         </a>
         ]. Median OS was approximately 41 and 36 months, respectively.
        </p>
        <p class="headingAnchor" id="H1089653137">
         <span class="h2">
          Adjuvant immunotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adjuvant checkpoint inhibitor immunotherapy with
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         (
         <a class="graphic graphic_table graphicRef134308" href="/z/d/graphic/134308.html" rel="external">
          table 2
         </a>
         ) or
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         (
         <a class="graphic graphic_table graphicRef131202" href="/z/d/graphic/131202.html" rel="external">
          table 3
         </a>
         ) is an established treatment option for patients with locoregionally advanced cutaneous melanoma, but data are limited for those with mucosal melanoma. Patients with mucosal melanoma can be evaluated for this approach, preferably in the context of clinical trial [
         <a href="#rid38">
          38
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7615.html" rel="external">
          "Adjuvant and neoadjuvant therapy for cutaneous melanoma"
         </a>
         .)
        </p>
        <p>
         As an example, only 29 patients with mucosal melanoma were included in a phase III trial evaluating adjuvant
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         in advanced melanoma (CheckMate 238). No patients with mucosal melanoma enrolled on a separate phase III trial evaluating adjuvant
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         (KEYNOTE-054). Further details on these trials are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7615.html" rel="external">
          "Adjuvant and neoadjuvant therapy for cutaneous melanoma", section on 'High-risk node-positive disease (stage IIIB, IIIC, IIID)'
         </a>
         .)
        </p>
        <p>
         For patients with resected locoregional mucosal melanoma and no distant metastases, limited data are also available for adjuvant
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         . The use of adjuvant nivolumab plus ipilimumab for this population is best evaluated in the context of a clinical trial. In a single-arm, open-label clinical trial (SALVO), 35 patients with resected mucosal melanoma were treated with four cycles of adjuvant nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) every three weeks followed by maintenance nivolumab [
         <a href="#rid133">
          133
         </a>
         ]. In this study, two-year recurrence-free and overall survival were 37 and 68 percent, respectively.
        </p>
        <p>
         The use of adjuvant
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         for metastatic cutaneous melanoma after definitive surgery or radiation therapy is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7615.html" rel="external">
          "Adjuvant and neoadjuvant therapy for cutaneous melanoma", section on 'Adjuvant nivolumab plus ipilimumab'
         </a>
         .)
        </p>
        <p>
         We do not offer
         <a class="drug drug_general" data-topicid="143227" href="/z/d/drug information/143227.html" rel="external">
          toripalimab
         </a>
         as adjuvant therapy for resected locoregional mucosal melanoma, as this approach failed to improve overall survival (OS) over adjuvant
         <a class="drug drug_general" data-topicid="8563" href="/z/d/drug information/8563.html" rel="external">
          interferon alfa-2b
         </a>
         in a randomized phase II trial [
         <a href="#rid134">
          134
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3306471">
         <span class="h1">
          SURVEILLANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surveillance for patients with mucosal melanoma is extrapolated from that used for patients with cutaneous melanoma. (See
         <a class="medical medical_review" href="/z/d/html/7621.html" rel="external">
          "Staging work-up and surveillance of cutaneous melanoma", section on 'Surveillance'
         </a>
         .)
        </p>
        <p>
         While there is clinical variability in the approach to surveillance, imaging strategies for mucosal melanoma should include imaging of the chest, abdomen and pelvis, and brain [
         <a href="#rid34">
          34
         </a>
         ]. For those with disease involving the head and neck, surveillance neck imaging should be included.
        </p>
        <p>
         Surveillance should also include routine examination of the oral mucosa as well as mirror and fiberoptic examination for mucosal melanomas arising from the head and neck, proctoscopy or sigmoidoscopy for anorectal mucosal melanoma, and speculum examination for vulvovaginal melanoma. These examinations are warranted because of the risk of locally recurrent disease and the relatively high incidence of multifocal disease in mucosal melanoma.
        </p>
        <p>
         In a retrospective study of 81 patients with mucosal melanoma identified the most common initial sites of metastasis as the lungs, liver, and nonregional lymph nodes, regardless of the primary site of disease. The rate of brain involvement as an initial site of metastasis was 7 percent, and no primary site was free of risk.
        </p>
        <p class="headingAnchor" id="H1689559730">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/118501.html" rel="external">
          "Society guideline links: Melanoma screening, prevention, diagnosis, and management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3876322585">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
        </p>
        <p>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/15499.html" rel="external">
          "Patient education: Melanoma skin cancer (The Basics)"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/892.html" rel="external">
          "Patient education: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/889.html" rel="external">
          "Patient education: Melanoma treatment; localized melanoma (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3306478">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – Mucosal melanoma is a rare disease that arises from the mucosal epithelium lining the respiratory, alimentary, and genitourinary tracts. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Epidemiology
         </strong>
         – It is more common in older adults and females, more likely to be multifocal and amelanotic, and generally has a worse prognosis than cutaneous melanoma. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Sites of disease
         </strong>
         – The most common sites of involvement are the head and neck, vulvovaginal, and anorectal regions. (See
         <a class="local">
          'Mucosal melanoma of the head and neck'
         </a>
         above and
         <a class="local">
          'Vulvovaginal melanoma'
         </a>
         above and
         <a class="local">
          'Anorectal melanoma'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of localized disease
         </strong>
         – For patients with locoregional disease of any primary site, initial management is complete wide local surgical resection. However, many still develop distant metastases despite adequate local primary disease control. (See
         <a class="local">
          'Surgical considerations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Head and neck melanoma
         </strong>
         – For patients with mucosal melanomas of the head and neck who are surgical candidates, we suggest surgery rather than radiation (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The surgical approach is the same as those with squamous cell carcinomas at the same anatomic site. (See
         <a class="local">
          'Management of locoregional disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Surgical management of the neck
         </strong>
         – The approach to management of the neck is as follows (see
         <a class="local">
          'Management of the neck'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Sinonasal disease and clinically negative nodes
         </strong>
         – We suggest surveillance alone rather than elective lymph node dissection (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Oral cavity disease and clinically negative nodes
         </strong>
         – We suggest elective lymph node dissection rather than observation (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Clinically evident nodes
         </strong>
         – Therapeutic neck dissection can be offered based on the need for local control and symptoms, although no overall survival (OS) benefit has been demonstrated.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Indications for adjuvant radiation therapy (RT)
         </strong>
         – For patients with resected high-risk disease (ie, palpable lymph nodes or extracapsular extension), we suggest adjuvant RT (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Adjuvant RT in such patients may decrease local recurrences, although no OS benefit has been demonstrated. (See
         <a class="local">
          'Adjuvant radiation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Nonsurgical candidates
         </strong>
         – For those who are not surgical candidates or in whom complete resection is not feasible, definitive RT is an alternative option for control of local disease. (See
         <a class="local">
          'Nonsurgical candidates'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vulvovaginal melanoma
         </strong>
         – For patients with vulvovaginal melanoma, we suggest wide local excision of the primary tumor rather than more radical surgeries (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Management of locoregional disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anorectal melanoma
         </strong>
         – For patients with anorectal melanoma, we suggest wide local excision with sphincter-sparing surgery rather than abdominoperineal resection (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Management of locoregional disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with clinically node-negative disease, we suggest against elective inguinal lymphadenectomy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ), given the morbidity of the surgery and lack of survival benefit. We reserve inguinal lymphadenectomy for those with clinically apparent nodal disease. (See
         <a class="local">
          'Indications for inguinal lymphadenectomy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Resected locoregional lymph nodes
         </strong>
         – For patients with positive locoregional lymph nodes treated with surgical resection, data on adjuvant therapy are limited, particularly in a Western patient population. Management decisions should be made on an individual patient basis. (See
         <a class="local">
          'Resected locoregional lymph nodes (adjuvant therapy)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          <em>
           BRAF
          </em>
         </strong>
         <strong>
          wild-type tumors
         </strong>
         – For those with
         <em>
          BRAF
         </em>
         wild-type mucosal melanoma, options include adjuvant chemotherapy (
         <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">
          temozolomide
         </a>
         plus
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         ) or adjuvant immunotherapy with
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         (
         <a class="graphic graphic_table graphicRef134308" href="/z/d/graphic/134308.html" rel="external">
          table 2
         </a>
         ) or
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         (
         <a class="graphic graphic_table graphicRef131202" href="/z/d/graphic/131202.html" rel="external">
          table 3
         </a>
         ); either treatment is reasonable in the absence of comparative data. (See
         <a class="local">
          'Adjuvant chemotherapy'
         </a>
         above and
         <a class="local">
          'Adjuvant immunotherapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Expectant observation may be offered to those who are ineligible for or decline adjuvant systemic therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          <em>
           BRAF
          </em>
         </strong>
         <strong>
          mutant tumors
         </strong>
         – Patients with a
         <em>
          BRAF
         </em>
         V600 mutation also have the option of adjuvant targeted therapy with
         <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">
          dabrafenib
         </a>
         plus
         <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">
          trametinib
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/7615.html" rel="external">
          "Adjuvant and neoadjuvant therapy for cutaneous melanoma", section on 'Adjuvant dabrafenib plus trametinib'
         </a>
         .)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998; 83:1664.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bishop KD, Olszewski AJ. Epidemiology and survival outcomes of ocular and mucosal melanomas: a population-based analysis. Int J Cancer 2014; 134:2961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patrick RJ, Fenske NA, Messina JL. Primary mucosal melanoma. J Am Acad Dermatol 2007; 56:828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McLaughlin CC, Wu XC, Jemal A, et al. Incidence of noncutaneous melanomas in the U.S. Cancer 2005; 103:1000.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meleti M, Leemans CR, de Bree R, et al. Head and neck mucosal melanoma: experience with 42 patients, with emphasis on the role of postoperative radiotherapy. Head Neck 2008; 30:1543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rapini RP, Golitz LE, Greer RO Jr, et al. Primary malignant melanoma of the oral cavity. A review of 177 cases. Cancer 1985; 55:1543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Padhye A, D'souza J. Oral malignant melanoma: A silent killer? J Indian Soc Periodontol 2011; 15:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smyth AG, Ward-Booth RP, Avery BS, To EW. Malignant melanoma of the oral cavity--an increasing clinical diagnosis? Br J Oral Maxillofac Surg 1993; 31:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sutherland CM, Chmiel JS, Henson DE, Winchester DP. Patient characteristics, methods of diagnosis, and treatment of mucous membrane melanoma in the United States of America. J Am Coll Surg 1994; 179:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pandey M, Mathew A, Abraham EK, et al. Primary malignant melanoma of the mucous membranes. Eur J Surg Oncol 1998; 24:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mundra PA, Dhomen N, Rodrigues M, et al. Ultraviolet radiation drives mutations in a subset of mucosal melanomas. Nat Commun 2021; 12:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lotem M, Anteby S, Peretz T, et al. Mucosal melanoma of the female genital tract is a multifocal disorder. Gynecol Oncol 2003; 88:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carvajal RD, Spencer SA, Lydiatt W. Mucosal melanoma: a clinically and biologically unique disease entity. J Natl Compr Canc Netw 2012; 10:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lian B, Cui CL, Zhou L, et al. The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients. Ann Oncol 2017; 28:868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuk D, Shoushtari AN, Barker CA, et al. Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis. Oncologist 2016; 21:848.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nathan P, Ascierto PA, Haanen J, et al. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). Eur J Cancer 2019; 119:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cress RD, Holly EA. Incidence of cutaneous melanoma among non-Hispanic whites, Hispanics, Asians, and blacks: an analysis of california cancer registry data, 1988-93. Cancer Causes Control 1997; 8:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bai X, Mao L, Guo J. Comments on Chinese guidelines for diagnosis and treatment of melanoma 2018 (English version). Chin J Cancer Res 2019; 31:740.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cui C, Wang X, Lian B, et al. A phase 2 clinical trial of neoadjuvant anti-PD-1 ab (Toripalimab) plus axitinib in resectable mucosal melanoma. J Clin Oncol 2021; 39;15S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manolidis S, Donald PJ. Malignant mucosal melanoma of the head and neck: review of the literature and report of 14 patients. Cancer 1997; 80:1373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nandapalan V, Roland NJ, Helliwell TR, et al. Mucosal melanoma of the head and neck. Clin Otolaryngol Allied Sci 1998; 23:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel SG, Prasad ML, Escrig M, et al. Primary mucosal malignant melanoma of the head and neck. Head Neck 2002; 24:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McLean N, Tighiouart M, Muller S. Primary mucosal melanoma of the head and neck. Comparison of clinical presentation and histopathologic features of oral and sinonasal melanoma. Oral Oncol 2008; 44:1039.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeMatos P, Tyler DS, Seigler HF. Malignant melanoma of the mucous membranes: a review of 119 cases. Ann Surg Oncol 1998; 5:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bachar G, Loh KS, O'Sullivan B, et al. Mucosal melanomas of the head and neck: experience of the Princess Margaret Hospital. Head Neck 2008; 30:1325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson IJ, Warfield AT, Smallman LA, Watkinson JC. Primary malignant melanoma of the pharynx. J Laryngol Otol 1994; 108:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amin HH, Petruzzelli GJ, Husain AN, Nickoloff BJ. Primary malignant melanoma of the larynx. Arch Pathol Lab Med 2001; 125:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Archer HA, Owen WJ. Primary malignant melanoma of the esophagus. Dis Esophagus 2000; 13:320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahn JY, Hwang HS, Park YS, et al. Endoscopic and pathologic findings associated with clinical outcomes of melanoma in the upper gastrointestinal tract. Ann Surg Oncol 2014; 21:2532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stern SJ, Guillamondegui OM. Mucosal melanoma of the head and neck. Head Neck 1991; 13:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee SP, Shimizu KT, Tran LM, et al. Mucosal melanoma of the head and neck: the impact of local control on survival. Laryngoscope 1994; 104:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moreno MA, Roberts DB, Kupferman ME, et al. Mucosal melanoma of the nose and paranasal sinuses, a contemporary experience from the M. D. Anderson Cancer Center. Cancer 2010; 116:2215.
          </a>
         </li>
         <li class="breakAll">
          NCCN Clinical Practice Guidelines in Oncology, Head and Neck Cancers. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf (Accessed on February 22, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shoushtari AN, Bluth MJ, Goldman DA, et al. Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma. Melanoma Res 2017; 27:57.
          </a>
         </li>
         <li class="breakAll">
          Lydiatt WM, Brandwein-Gensler M, Kraus DH, et al. Mucosal melanoma of the head and neck. In: AJCC Cancer Staging Manual, 8th ed, Amin MB (Ed), Springer, New York 2017. p.163.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prasad ML, Patel SG, Huvos AG, et al. Primary mucosal melanoma of the head and neck: a proposal for microstaging localized, Stage I (lymph node-negative) tumors. Cancer 2004; 100:1657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson LD, Wieneke JA, Miettinen M. Sinonasal tract and nasopharyngeal melanomas: a clinicopathologic study of 115 cases with a proposed staging system. Am J Surg Pathol 2003; 27:594.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nenclares P, Ap Dafydd D, Bagwan I, et al. Head and neck mucosal melanoma: The United Kingdom national guidelines. Eur J Cancer 2020; 138:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ganly I, Patel SG, Singh B, et al. Craniofacial resection for malignant melanoma of the skull base: report of an international collaborative study. Arch Otolaryngol Head Neck Surg 2006; 132:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lund VJ, Howard DJ, Harding L, Wei WI. Management options and survival in malignant melanoma of the sinonasal mucosa. Laryngoscope 1999; 109:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanna E, DeMonte F, Ibrahim S, et al. Endoscopic resection of sinonasal cancers with and without craniotomy: oncologic results. Arch Otolaryngol Head Neck Surg 2009; 135:1219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panje WR, Moran WJ. Melanoma of the upper aerodigestive tract: a review of 21 cases. Head Neck Surg 1986; 8:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krengli M, Masini L, Kaanders JH, et al. Radiotherapy in the treatment of mucosal melanoma of the upper aerodigestive tract: analysis of 74 cases. A Rare Cancer Network study. Int J Radiat Oncol Biol Phys 2006; 65:751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loree TR, Mullins AP, Spellman J, et al. Head and neck mucosal melanoma: a 32-year review. Ear Nose Throat J 1999; 78:372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Virgilio A, Costantino A, Canzano F, et al. Regional disease control in sinonasal mucosal melanoma: Systematic review and meta-analysis. Head Neck 2021; 43:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Medina JE, Ferlito A, Pellitteri PK, et al. Current management of mucosal melanoma of the head and neck. J Surg Oncol 2003; 83:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stárek I, Koranda P, Benes P. Sentinel lymph node biopsy: A new perspective in head and neck mucosal melanoma? Melanoma Res 2006; 16:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baptista P, Garcia Velloso MJ, Salvinelli F, Casale M. Radioguided surgical strategy in mucosal melanoma of the nasal cavity. Clin Nucl Med 2008; 33:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Owens JM, Roberts DB, Myers JN. The role of postoperative adjuvant radiation therapy in the treatment of mucosal melanomas of the head and neck region. Arch Otolaryngol Head Neck Surg 2003; 129:864.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakashima JP, Viégas CM, Fassizoli AL, et al. Postoperative adjuvant radiation therapy in the treatment of primary head and neck mucosal melanomas. ORL J Otorhinolaryngol Relat Spec 2008; 70:344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Temam S, Mamelle G, Marandas P, et al. Postoperative radiotherapy for primary mucosal melanoma of the head and neck. Cancer 2005; 103:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benlyazid A, Thariat J, Temam S, et al. Postoperative radiotherapy in head and neck mucosal melanoma: a GETTEC study. Arch Otolaryngol Head Neck Surg 2010; 136:1219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yii NW, Eisen T, Nicolson M, et al. Mucosal malignant melanoma of the head and neck: the Marsden experience over half a century. Clin Oncol (R Coll Radiol) 2003; 15:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caspers CJI, Dronkers EAC, Monserez D, et al. Adjuvant radiotherapy in sinonasal mucosal melanoma: A retrospective analysis. Clin Otolaryngol 2018; 43:617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grant-Freemantle MC, Lane O'Neill B, Clover AJP. The effectiveness of radiotherapy in the treatment of head and neck mucosal melanoma: Systematic review and meta-analysis. Head Neck 2021; 43:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu AJ, Gomez J, Zhung JE, et al. Radiotherapy after surgical resection for head and neck mucosal melanoma. Am J Clin Oncol 2010; 33:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wada H, Nemoto K, Ogawa Y, et al. A multi-institutional retrospective analysis of external radiotherapy for mucosal melanoma of the head and neck in Northern Japan. Int J Radiat Oncol Biol Phys 2004; 59:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koto M, Demizu Y, Saitoh JI, et al. Multicenter Study of Carbon-Ion Radiation Therapy for Mucosal Melanoma of the Head and Neck: Subanalysis of the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS) Study (1402 HN). Int J Radiat Oncol Biol Phys 2017; 97:1054.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng YF, Lai CC, Ho CY, et al. Toward a better understanding of sinonasal mucosal melanoma: clinical review of 23 cases. J Chin Med Assoc 2007; 70:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dauer EH, Lewis JE, Rohlinger AL, et al. Sinonasal melanoma: a clinicopathologic review of 61 cases. Otolaryngol Head Neck Surg 2008; 138:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samstein RM, Carvajal RD, Postow MA, et al. Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response. Head Neck 2016; 38:1310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Creasman WT, Phillips JL, Menck HR. A survey of hospital management practices for vulvar melanoma. J Am Coll Surg 1999; 188:670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stang A, Streller B, Eisinger B, Jöckel KH. Population-based incidence rates of malignant melanoma of the vulva in Germany. Gynecol Oncol 2005; 96:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katz EE, Suzue K, Wille MA, et al. Primary malignant melanoma of the urethra. Urology 2005; 65:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kojima T, Tanaka T, Yoshimi N, Mori H. Primary malignant melanoma of the urinary bladder. Arch Pathol Lab Med 1992; 116:1213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khalbuss WE, Hossain M, Elhosseiny A. Primary malignant melanoma of the urinary bladder diagnosed by urine cytology: a case report. Acta Cytol 2001; 45:631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clark KC, Butz WR, Hapke MR. Primary malignant melanoma of the uterine cervix: case report with world literature review. Int J Gynecol Pathol 1999; 18:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cantuaria G, Angioli R, Nahmias J, et al. Primary malignant melanoma of the uterine cervix: case report and review of the literature. Gynecol Oncol 1999; 75:170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piura B, Egan M, Lopes A, Monaghan JM. Malignant melanoma of the vulva: a clinicopathologic study of 18 cases. J Surg Oncol 1992; 50:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piura B, Rabinovich A, Dgani R. Malignant melanoma of the vulva: report of six cases and review of the literature. Eur J Gynaecol Oncol 1999; 20:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verschraegen CF, Benjapibal M, Supakarapongkul W, et al. Vulvar melanoma at the M. D. Anderson Cancer Center: 25 years later. Int J Gynecol Cancer 2001; 11:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piura B, Rabinovich A, Yanai-Inbar I. Primary malignant melanoma of the vagina: case report and review of literature. Eur J Gynaecol Oncol 2002; 23:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sugiyama VE, Chan JK, Shin JY, et al. Vulvar melanoma: a multivariable analysis of 644 patients. Obstet Gynecol 2007; 110:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borazjani G, Prem KA, Okagaki T, et al. Primary malignant melanoma of the vagina: a clinicopathological analysis of 10 cases. Gynecol Oncol 1990; 37:264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ragnarsson-Olding BK, Kanter-Lewensohn LR, Lagerlöf B, et al. Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females: clinical observations and histopathologic features. Cancer 1999; 86:1273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wechter ME, Gruber SB, Haefner HK, et al. Vulvar melanoma: a report of 20 cases and review of the literature. J Am Acad Dermatol 2004; 50:554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969; 29:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172:902.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung AF, Woodruff JM, Lewis JL Jr. Malignant melanoma of the vulva: A report of 44 cases. Obstet Gynecol 1975; 45:638.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phillips GL, Bundy BN, Okagaki T, et al. Malignant melanoma of the vulva treated by radical hemivulvectomy. A prospective study of the Gynecologic Oncology Group. Cancer 1994; 73:2626.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moxley KM, Fader AN, Rose PG, et al. Malignant melanoma of the vulva: an extension of cutaneous melanoma? Gynecol Oncol 2011; 122:612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seifried S, Haydu LE, Quinn MJ, et al. Melanoma of the vulva and vagina: principles of staging and their relevance to management based on a clinicopathologic analysis of 85 cases. Ann Surg Oncol 2015; 22:1959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ballantyne AJ. Malignant melanoma of the skin of the head and neck. An analysis of 405 cases. Am J Surg 1970; 120:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buchanan DJ, Schlaerth J, Kurosaki T. Primary vaginal melanoma: thirteen-year disease-free survival after wide local excision and review of recent literature. Am J Obstet Gynecol 1998; 178:1177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petru E, Nagele F, Czerwenka K, et al. Primary malignant melanoma of the vagina: long-term remission following radiation therapy. Gynecol Oncol 1998; 70:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith HG, Bagwan I, Board RE, et al. Ano-uro-genital mucosal melanoma UK national guidelines. Eur J Cancer 2020; 135:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Irvin WP Jr, Legallo RL, Stoler MH, et al. Vulvar melanoma: a retrospective analysis and literature review. Gynecol Oncol 2001; 83:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trimble EL. Melanomas of the vulva and vagina. Oncology (Williston Park) 1996; 10:1017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeMatos P, Tyler D, Seigler HF. Mucosal melanoma of the female genitalia: a clinicopathologic study of forty-three cases at Duke University Medical Center. Surgery 1998; 124:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ragnarsson-Olding BK, Nilsson BR, Kanter-Lewensohn LR, et al. Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females: predictors of survival. Cancer 1999; 86:1285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miner TJ, Delgado R, Zeisler J, et al. Primary vaginal melanoma: a critical analysis of therapy. Ann Surg Oncol 2004; 11:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suwandinata FS, Bohle RM, Omwandho CA, et al. Management of vulvar melanoma and review of the literature. Eur J Gynaecol Oncol 2007; 28:220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradgate MG, Rollason TP, McConkey CC, Powell J. Malignant melanoma of the vulva: a clinicopathological study of 50 women. Br J Obstet Gynaecol 1990; 97:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trimble EL, Lewis JL Jr, Williams LL, et al. Management of vulvar melanoma. Gynecol Oncol 1992; 45:254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janco JM, Markovic SN, Weaver AL, Cliby WA. Vulvar and vaginal melanoma: case series and review of current management options including neoadjuvant chemotherapy. Gynecol Oncol 2013; 129:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Irvin WP Jr, Bliss SA, Rice LW, et al. Malignant melanoma of the vagina and locoregional control: radical surgery revisited. Gynecol Oncol 1998; 71:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Hullu JA, Hollema H, Hoekstra HJ, et al. Vulvar melanoma: is there a role for sentinel lymph node biopsy? Cancer 2002; 94:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dhar KK, DAS N, Brinkman DA, et al. Utility of sentinel node biopsy in vulvar and vaginal melanoma: report of two cases and review of the literature. Int J Gynecol Cancer 2007; 17:720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaramillo BA, Ganjei P, Averette HE, et al. Malignant melanoma of the vulva. Obstet Gynecol 1985; 66:398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gökaslan H, Sişmanoğlu A, Pekin T, et al. Primary malignant melanoma of the vagina: a case report and review of the current treatment options. Eur J Obstet Gynecol Reprod Biol 2005; 121:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonner JA, Perez-Tamayo C, Reid GC, et al. The management of vaginal melanoma. Cancer 1988; 62:2066.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinstock MA. Malignant melanoma of the vulva and vagina in the United States: patterns of incidence and population-based estimates of survival. Am J Obstet Gynecol 1994; 171:1225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Creasman WT, Phillips JL, Menck HR. The National Cancer Data Base report on cancer of the vagina. Cancer 1998; 83:1033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frumovitz M, Etchepareborda M, Sun CC, et al. Primary malignant melanoma of the vagina. Obstet Gynecol 2010; 116:1358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cagir B, Whiteford MH, Topham A, et al. Changing epidemiology of anorectal melanoma. Dis Colon Rectum 1999; 42:1203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coté TR, Sobin LH. Primary melanomas of the esophagus and anorectum: epidemiologic comparison with melanoma of the skin. Melanoma Res 2009; 19:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burgi A, Brodine S, Wegner S, et al. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer 2005; 104:1505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bello DM, Smyth E, Perez D, et al. Anal versus rectal melanoma: does site of origin predict outcome? Dis Colon Rectum 2013; 56:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iddings DM, Fleisig AJ, Chen SL, et al. Practice patterns and outcomes for anorectal melanoma in the USA, reviewing three decades of treatment: is more extensive surgical resection beneficial in all patients? Ann Surg Oncol 2010; 17:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pessaux P, Pocard M, Elias D, et al. Surgical management of primary anorectal melanoma. Br J Surg 2004; 91:1183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooper PH, Mills SE, Allen MS Jr. Malignant melanoma of the anus: report of 12 patients and analysis of 255 additional cases. Dis Colon Rectum 1982; 25:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinstock MA. Epidemiology and prognosis of anorectal melanoma. Gastroenterology 1993; 104:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldman S, Glimelius B, Påhlman L. Anorectal malignant melanoma in Sweden. Report of 49 patients. Dis Colon Rectum 1990; 33:874.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ross M, Pezzi C, Pezzi T, et al. Patterns of failure in anorectal melanoma. A guide to surgical therapy. Arch Surg 1990; 125:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singer M, Mutch MG. Anal melanoma. Clin Colon Rectal Surg 2006; 19:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brady MS, Kavolius JP, Quan SH. Anorectal melanoma. A 64-year experience at Memorial Sloan-Kettering Cancer Center. Dis Colon Rectum 1995; 38:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeh JJ, Shia J, Hwu WJ, et al. The role of abdominoperineal resection as surgical therapy for anorectal melanoma. Ann Surg 2006; 244:1012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ballo MT, Gershenwald JE, Zagars GK, et al. Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. J Clin Oncol 2002; 20:4555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagarajan P, Piao J, Ning J, et al. Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. Mod Pathol 2020; 33:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsuda A, Miyashita M, Matsumoto S, et al. Abdominoperineal resection provides better local control but equivalent overall survival to local excision of anorectal malignant melanoma: a systematic review. Ann Surg 2015; 261:670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roumen RM. Anorectal melanoma in The Netherlands: a report of 63 patients. Eur J Surg Oncol 1996; 22:598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nilsson PJ, Ragnarsson-Olding BK. Importance of clear resection margins in anorectal malignant melanoma. Br J Surg 2010; 97:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Droesch JT, Flum DR, Mann GN. Wide local excision or abdominoperineal resection as the initial treatment for anorectal melanoma? Am J Surg 2005; 189:446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tien HY, McMasters KM, Edwards MJ, Chao C. Sentinel lymph node metastasis in anal melanoma: a case report. Int J Gastrointest Cancer 2002; 32:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perez DR, Trakarnsanga A, Shia J, et al. Locoregional lymphadenectomy in the surgical management of anorectal melanoma. Ann Surg Oncol 2013; 20:2339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tchelebi L, Guirguis A, Ashamalla H. Rectal melanoma: epidemiology, prognosis, and role of adjuvant radiation therapy. J Cancer Res Clin Oncol 2016; 142:2569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly P, Zagars GK, Cormier JN, et al. Sphincter-sparing local excision and hypofractionated radiation therapy for anorectal melanoma: A 20-year experience. Cancer 2011; 117:4747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thibault C, Sagar P, Nivatvongs S, et al. Anorectal melanoma--an incurable disease? Dis Colon Rectum 1997; 40:661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen F, Zhang Q, Wang Y, et al. KIT, NRAS, BRAF and FMNL2 mutations in oral mucosal melanoma and a systematic review of the literature. Oncol Lett 2018; 15:9786.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lian B, Si L, Cui C, et al. Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma. Clin Cancer Res 2013; 19:4488.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lian B, Cui C, Song X, et al. Phase Ⅲ randomized, multicenter trial comparing high-dose IFN-a2b with temozolomide plus cisplatin as adjuvant therapy for resected mucosal melanoma. J Clin Oncol 2018; 36;S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kottschade LA, Pond GR, Olszanski AJ, et al. SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma. Clin Cancer Res 2023; 29:2220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lian B, Si L, Chi ZH, et al. Toripalimab (anti-PD-1) versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial. Ann Oncol 2022; 33:1061.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 16904 Version 47.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9781962" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24272143" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Epidemiology and survival outcomes of ocular and mucosal melanomas: a population-based analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17349716" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Primary mucosal melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15651058" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Incidence of noncutaneous melanomas in the U.S.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18704960" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Head and neck mucosal melanoma: experience with 42 patients, with emphasis on the role of postoperative radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3978548" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Primary malignant melanoma of the oral cavity. A review of 177 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22368374" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Oral malignant melanoma: A silent killer?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8399039" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Malignant melanoma of the oral cavity--an increasing clinical diagnosis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7952459" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Patient characteristics, methods of diagnosis, and treatment of mucous membrane melanoma in the United States of America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9724998" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Primary malignant melanoma of the mucous membranes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33431815" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Ultraviolet radiation drives mutations in a subset of mucosal melanomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12504626" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Mucosal melanoma of the female genital tract is a multifocal disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22393195" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Mucosal melanoma: a clinically and biologically unique disease entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28039178" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27286787" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31445199" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9134249" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Incidence of cutaneous melanoma among non-Hispanic whites, Hispanics, Asians, and blacks: an analysis of california cancer registry data, 1988-93.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31814677" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Comments on Chinese guidelines for diagnosis and treatment of melanoma 2018 (English version).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : A phase 2 clinical trial of neoadjuvant anti-PD-1 ab (Toripalimab) plus axitinib in resectable mucosal melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9338460" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Malignant mucosal melanoma of the head and neck: review of the literature and report of 14 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9597279" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Mucosal melanoma of the head and neck.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11891956" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Primary mucosal malignant melanoma of the head and neck.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18396446" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Primary mucosal melanoma of the head and neck. Comparison of clinical presentation and histopathologic features of oral and sinonasal melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9869521" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Malignant melanoma of the mucous membranes: a review of 119 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18704964" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Mucosal melanomas of the head and neck: experience of the Princess Margaret Hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8169521" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Primary malignant melanoma of the pharynx.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11175650" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Primary malignant melanoma of the larynx.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11284983" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Primary malignant melanoma of the esophagus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24633670" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Endoscopic and pathologic findings associated with clinical outcomes of melanoma in the upper gastrointestinal tract.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1989926" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Mucosal melanoma of the head and neck.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8302112" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Mucosal melanoma of the head and neck: the impact of local control on survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20198705" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Mucosal melanoma of the nose and paranasal sinuses, a contemporary experience from the M. D. Anderson Cancer Center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20198705" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Mucosal melanoma of the nose and paranasal sinuses, a contemporary experience from the M. D. Anderson Cancer Center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27792058" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27792058" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15073854" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Primary mucosal melanoma of the head and neck: a proposal for microstaging localized, Stage I (lymph node-negative) tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12717245" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Sinonasal tract and nasopharyngeal melanomas: a clinicopathologic study of 115 cases with a proposed staging system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32829104" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Head and neck mucosal melanoma: The United Kingdom national guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16415433" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Craniofacial resection for malignant melanoma of the skull base: report of an international collaborative study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10890767" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Management options and survival in malignant melanoma of the sinonasal mucosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20026819" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Endoscopic resection of sinonasal cancers with and without craniotomy: oncologic results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3744859" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Melanoma of the upper aerodigestive tract: a review of 21 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16647223" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Radiotherapy in the treatment of mucosal melanoma of the upper aerodigestive tract: analysis of 74 cases. A Rare Cancer Network study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10355199" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Head and neck mucosal melanoma: a 32-year review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33151611" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Regional disease control in sinonasal mucosal melanoma: Systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12772206" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Current management of mucosal melanoma of the head and neck.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17013091" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Sentinel lymph node biopsy: A new perspective in head and neck mucosal melanoma?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18097249" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Radioguided surgical strategy in mucosal melanoma of the nasal cavity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12925346" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : The role of postoperative adjuvant radiation therapy in the treatment of mucosal melanomas of the head and neck region.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18984969" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Postoperative adjuvant radiation therapy in the treatment of primary head and neck mucosal melanomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15578718" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Postoperative radiotherapy for primary mucosal melanoma of the head and neck.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21173371" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Postoperative radiotherapy in head and neck mucosal melanoma: a GETTEC study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12846499" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Mucosal malignant melanoma of the head and neck: the Marsden experience over half a century.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29150980" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Adjuvant radiotherapy in sinonasal mucosal melanoma: A retrospective analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32926490" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : The effectiveness of radiotherapy in the treatment of head and neck mucosal melanoma: Systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19823070" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Radiotherapy after surgical resection for head and neck mucosal melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15145168" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : A multi-institutional retrospective analysis of external radiotherapy for mucosal melanoma of the head and neck in Northern Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28332989" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Multicenter Study of Carbon-Ion Radiation Therapy for Mucosal Melanoma of the Head and Neck: Subanalysis of the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS) Study (1402 HN).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17276929" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Toward a better understanding of sinonasal mucosal melanoma: clinical review of 23 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18312883" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Sinonasal melanoma: a clinicopathologic review of 61 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27043023" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10359360" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : A survey of hospital management practices for vulvar melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15589604" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Population-based incidence rates of malignant melanoma of the vulva in Germany.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15708067" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Primary malignant melanoma of the urethra.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1444751" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Primary malignant melanoma of the urinary bladder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11480732" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Primary malignant melanoma of the urinary bladder diagnosed by urine cytology: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12090596" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Primary malignant melanoma of the uterine cervix: case report with world literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10502448" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Primary malignant melanoma of the uterine cervix: case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1640707" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Malignant melanoma of the vulva: a clinicopathologic study of 18 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10410880" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Malignant melanoma of the vulva: report of six cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11737466" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Vulvar melanoma at the M. D. Anderson Cancer Center: 25 years later.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12094953" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Primary malignant melanoma of the vagina: case report and review of literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17666603" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Vulvar melanoma: a multivariable analysis of 644 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2344972" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Primary malignant melanoma of the vagina: a clinicopathological analysis of 10 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10506714" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females: clinical observations and histopathologic features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15034504" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Vulvar melanoma: a report of 20 cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11504745" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5773814" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : The histogenesis and biologic behavior of primary human malignant melanomas of the skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5477666" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1143724" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Malignant melanoma of the vulva: A report of 44 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8174062" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Malignant melanoma of the vulva treated by radical hemivulvectomy. A prospective study of the Gynecologic Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21570710" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Malignant melanoma of the vulva: an extension of cutaneous melanoma?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25384702" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Melanoma of the vulva and vagina: principles of staging and their relevance to management based on a clinicopathologic analysis of 85 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5507326" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Malignant melanoma of the skin of the head and neck. An analysis of 405 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9662299" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Primary vaginal melanoma: thirteen-year disease-free survival after wide local excision and review of recent literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9698468" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Primary malignant melanoma of the vagina: long-term remission following radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32531566" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Ano-uro-genital mucosal melanoma UK national guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11733955" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Vulvar melanoma: a retrospective analysis and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8837119" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Melanomas of the vulva and vagina.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9663250" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Mucosal melanoma of the female genitalia: a clinicopathologic study of forty-three cases at Duke University Medical Center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10506715" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females: predictors of survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14699031" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Primary vaginal melanoma: a critical analysis of therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17624092" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Management of vulvar melanoma and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2317465" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Malignant melanoma of the vulva: a clinicopathological study of 50 women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1612500" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Management of vulvar melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23480869" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Vulvar and vaginal melanoma: case series and review of current management options including neoadjuvant chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9887254" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Malignant melanoma of the vagina and locoregional control: radical surgery revisited.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11905414" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Vulvar melanoma: is there a role for sentinel lymph node biopsy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17343569" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Utility of sentinel node biopsy in vulvar and vaginal melanoma: report of two cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4022497" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Malignant melanoma of the vulva.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16054970" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Primary malignant melanoma of the vagina: a case report and review of the current treatment options.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3167819" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : The management of vaginal melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7977524" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Malignant melanoma of the vulva and vagina in the United States: patterns of incidence and population-based estimates of survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9731908" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : The National Cancer Data Base report on cancer of the vagina.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21099603" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Primary malignant melanoma of the vagina.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10496563" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Changing epidemiology of anorectal melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19430407" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Primary melanomas of the esophagus and anorectum: epidemiologic comparison with melanoma of the skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16104038" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23303142" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Anal versus rectal melanoma: does site of origin predict outcome?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19774417" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Practice patterns and outcomes for anorectal melanoma in the USA, reviewing three decades of treatment: is more extensive surgical resection beneficial in all patients?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15449271" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Surgical management of primary anorectal melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7128372" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Malignant melanoma of the anus: report of 12 patients and analysis of 255 additional cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8419240" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Epidemiology and prognosis of anorectal melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1698595" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Anorectal malignant melanoma in Sweden. Report of 49 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2306178" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Patterns of failure in anorectal melanoma. A guide to surgical therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20011314" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Anal melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7851168" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Anorectal melanoma. A 64-year experience at Memorial Sloan-Kettering Cancer Center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17122627" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : The role of abdominoperineal resection as surgical therapy for anorectal melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12454112" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31383963" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25119122" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Abdominoperineal resection provides better local control but equivalent overall survival to local excision of anorectal malignant melanoma: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9005147" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Anorectal melanoma in The Netherlands: a report of 63 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20013935" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Importance of clear resection margins in anorectal malignant melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15820458" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Wide local excision or abdominoperineal resection as the initial treatment for anorectal melanoma?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12630771" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Sentinel lymph node metastasis in anal melanoma: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23328972" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Locoregional lymphadenectomy in the surgical management of anorectal melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27620741" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Rectal melanoma: epidemiology, prognosis, and role of adjuvant radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21446049" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Sphincter-sparing local excision and hypofractionated radiation therapy for anorectal melanoma: A 20-year experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9194459" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Anorectal melanoma--an incurable disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29805686" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : KIT, NRAS, BRAF and FMNL2 mutations in oral mucosal melanoma and a systematic review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23833309" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : PhaseⅢrandomized, multicenter trial comparing high-dose IFN-a2b with temozolomide plus cisplatin as adjuvant therapy for resected mucosal melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37000165" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35842199" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Toripalimab (anti-PD-1) versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
